KR20060014444A - 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도 - Google Patents

멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도 Download PDF

Info

Publication number
KR20060014444A
KR20060014444A KR1020057024261A KR20057024261A KR20060014444A KR 20060014444 A KR20060014444 A KR 20060014444A KR 1020057024261 A KR1020057024261 A KR 1020057024261A KR 20057024261 A KR20057024261 A KR 20057024261A KR 20060014444 A KR20060014444 A KR 20060014444A
Authority
KR
South Korea
Prior art keywords
arg
cys
phe
fmoc
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057024261A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 벤자민 플로라
마크 루이스 헤이만
쟌느 엘. 헤르텔
한센 맥스웰 슝
존 필립 메이어
데이비드 리 스마일리
리안 쩡 얀
리안샨 장
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20060014444A publication Critical patent/KR20060014444A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020057024261A 2003-06-19 2004-06-17 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도 Ceased KR20060014444A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US47974003P 2003-06-19 2003-06-19
US60/479,740 2003-06-19
US55734704P 2004-03-29 2004-03-29
US60/557,347 2004-03-29
US57073704P 2004-05-13 2004-05-13
US57067604P 2004-05-13 2004-05-13
US60/570,676 2004-05-13
US60/570,737 2004-05-13

Publications (1)

Publication Number Publication Date
KR20060014444A true KR20060014444A (ko) 2006-02-15

Family

ID=33556652

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057024261A Ceased KR20060014444A (ko) 2003-06-19 2004-06-17 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도

Country Status (17)

Country Link
US (1) US20070105759A1 (https=)
EP (1) EP1644023A2 (https=)
JP (1) JP2006527773A (https=)
KR (1) KR20060014444A (https=)
AR (1) AR044824A1 (https=)
AU (1) AU2004251616A1 (https=)
BR (1) BRPI0410731A (https=)
CA (1) CA2530024A1 (https=)
CR (1) CR8159A (https=)
EA (1) EA200600055A1 (https=)
EC (1) ECSP056236A (https=)
IL (1) IL171931A0 (https=)
MX (1) MXPA05013951A (https=)
NO (1) NO20060259L (https=)
PE (1) PE20050284A1 (https=)
TW (1) TW200514791A (https=)
WO (1) WO2005000339A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110040819A (ko) * 2008-06-09 2011-04-20 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
KR20120092089A (ko) * 2009-06-08 2012-08-20 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
KR20190022305A (ko) * 2017-08-24 2019-03-06 한국콜마주식회사 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658285B1 (en) 2003-08-20 2007-05-02 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
ATE350369T1 (de) 2003-08-20 2007-01-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4- rezeptor (mc4) als agonist wirkenden peptids
WO2006073772A1 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
NZ565217A (en) * 2005-07-08 2010-03-26 Ipsen Pharma Sas Melanocortin receptor ligands
JP2009500426A (ja) * 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
TWI364290B (en) * 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0819188B1 (pt) 2007-11-05 2021-06-22 Ipsen Pharma S.A.S. Uso de melanocortinas para a preparação de um medicamento para tratar resistência à insulina
CN101918545A (zh) 2008-01-02 2010-12-15 丹尼斯科美国公司 应用嗜糖假单胞菌g4-淀粉酶和其变体获得乙醇的无葡糖淀粉酶的方法
WO2009151383A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
JP5999702B2 (ja) 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−１受容体特異的環状ペプチド
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
LT3539551T (lt) 2011-12-29 2022-01-10 Rhythm Pharmaceuticals, Inc. Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CN115957297A (zh) * 2013-03-15 2023-04-14 节奏制药公司 药物组合物
EP2970388B1 (en) * 2013-03-15 2018-07-25 Rhythm Pharmaceuticals, Inc. Peptide compositions
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
PL3356386T3 (pl) 2015-09-30 2024-08-05 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych ze szlakiem receptora melanokortyny 4
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
CN115010793A (zh) * 2022-06-17 2022-09-06 中国农业大学 玫瑰叶畸形病毒外壳蛋白多克隆抗体的制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485039A (en) * 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
GB9808229D0 (en) * 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
EP1137340A4 (en) * 1998-12-09 2005-12-21 Eleanor Roosevelt Inst COMPOSITION AND METHODS FOR REGULATION OF BODY WEIGHT AND ASSOCIATED PATHOLOGIES
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
GB9827500D0 (en) * 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
CA2368431C (en) * 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6659982B2 (en) * 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
SI1315750T1 (sl) * 2000-08-30 2007-06-30 Hoffmann La Roche Cikliäśni peptidi kot agonisti za receptorje melanokortina-4
US6960646B2 (en) * 2001-07-12 2005-11-01 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptors agonists

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110040819A (ko) * 2008-06-09 2011-04-20 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
KR20120092089A (ko) * 2009-06-08 2012-08-20 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
KR20190022305A (ko) * 2017-08-24 2019-03-06 한국콜마주식회사 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물
KR20190022306A (ko) * 2017-08-24 2019-03-06 한국콜마주식회사 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물
US11242366B2 (en) 2017-08-24 2022-02-08 Kolmar Korea Co., Ltd. Microcapsule including peptide having cell receptor binding affinity and cosmetic composition containing same

Also Published As

Publication number Publication date
PE20050284A1 (es) 2005-05-20
CR8159A (es) 2006-02-09
WO2005000339A2 (en) 2005-01-06
EA200600055A1 (ru) 2006-08-25
CA2530024A1 (en) 2005-01-06
EP1644023A2 (en) 2006-04-12
US20070105759A1 (en) 2007-05-10
AU2004251616A1 (en) 2005-01-06
IL171931A0 (en) 2006-04-10
ECSP056236A (es) 2006-04-19
WO2005000339A3 (en) 2005-02-03
JP2006527773A (ja) 2006-12-07
NO20060259L (no) 2006-03-14
TW200514791A (en) 2005-05-01
WO2005000339A8 (en) 2005-04-21
AR044824A1 (es) 2005-10-05
BRPI0410731A (pt) 2006-06-20
MXPA05013951A (es) 2006-02-24

Similar Documents

Publication Publication Date Title
KR20060014444A (ko) 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도
RU2381233C2 (ru) Агонисты рецептора меланокортина
DE60038734T2 (de) Melanocortinrezeptor-liganden
US20080269114A1 (en) Y4 Selective Receptor Agonists For Thereapeutic Interventions
CN104822702B (zh) α-MSH和γ-MSH类似物
JP2009508885A (ja) 治療的介入のためのｙ４選択性レセプターアゴニスト
WO2014144842A2 (en) Pharmaceutical compositions
CN101268096A (zh) 用于治疗性干预的y2选择性受体激动剂
Wiśniewski Design of oxytocin analogs
WO2018128828A1 (en) Novel hepcidin mimetics and uses thereof
WO2005000877A2 (en) Novel melanocortin receptor templates, peptides, and use thereof
JP2007531713A6 (ja) 治療的介入のためのｙ２選択性レセプターアゴニスト
CN100425282C (zh) 用于治疗性干预的y2/y4选择性受体激动剂
CN112876552A (zh) 长效肾上腺髓质素衍生物
US20080261871A1 (en) Y2/Y4 Selective Receptor Agonists for Therapeutic Interventions
US20060293223A1 (en) Uses of melanocortin-3 receptor (mc3r) agonist peptides
JP2023544959A (ja) 改善されたアミリン受容体（ｈＡＭＹ３Ｒ）効力を有するｈＡＭ１５－５２類似体
US5869450A (en) Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
US20080280820A1 (en) Novel Peptides for Use in the Treatment of Obesity
JP2023509383A (ja) レトロインベルソペプチド
IL295151A (en) Diamine-related receptor-specific cyclic peptides
CN110678550A (zh) 长效肾上腺髓质素衍生物
WO1997032898A9 (en) Anti-inflammatory crf analogs, their compositions and use
WO2006073772A1 (en) Polyethylene glycol linked mc4r or mc3r agonist peptides
US11612661B2 (en) Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051216

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060131

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070215

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20070601

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20070215

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I